Thrombopoietin Receptor Agonists Market to Hit $3.74 Bn by 2034

Thrombopoietin Receptor Agonists Market Companies, Shares and Trends

The global thrombopoietin receptor agonists market was estimated at US$ 1.85 billion in 2023 and is projected to grow to US$ 3.74 billion by 2034, rising at a compound annual growth rate (CAGR) of 6.6% from 2024 to 2034. The thrombopoietin receptor agonist drugs are in high demand because they are used for increasing the platelet count, which decreases various health issues.

Unlock Infinite Advantages: Subscribe to Annual Membership

Market Overview

The global thrombopoietin receptor agonists market is responsible for the production, distribution, and R&D of thrombopoietin receptor agonists (TPO-RAs) drugs in oral or injectable forms. TPO-RAs are used for increasing platelet counts and in preventing bleeding. The U.S. FDA and the European Medicines Agency have approved or not approved different TPO-RAs for different health issues. In the future, in-depth research and knowledge can be gathered on the TPO-RAs class, which will be useful in empowering healthcare professionals and pharmacists to make evidence-based and informed decisions with individual patients, enabling patient-centered care.

Thrombopoietin Receptor Agonists Market Trends

• In May 2024, Amgen released financial data for the first quarter of 2024. Sales of Nplate® (romiplostim) totaled $317 million during the first quarter. The volume increase was the main driver of Nplate sales' 13% annual rise when the U.S. government order was excluded from the comparison.
• In January 2023, Intas Pharmaceuticals introduced the biosimilar romiplostim in India, and retrospective research that was published in the Indian Journal of Pathology & Microbiology revealed that it was beneficial for adult Indian patients suffering from immune thrombocytopenia (ITP).

Market Opportunity: Gaining Approval

One of the challenges faced by the thrombopoietin receptor agonists market is that the drugs are not approved in all countries. The U.S. FDA and the European Medicines Agency have approved certain drugs, but not for all the health issues. This creates a potential growth opportunity for the market. Organizations, government agencies, and research can, individually or in collaboration, conduct research and develop better TPO-RA drugs in order to get approval from governments. Due to this, the drugs will be used in more countries and for a variety of health conditions.

Thrombopoietin Receptor Agonists Market Challenge: Safety Issues

There are certain adverse reactions caused by the use of TPO-RAs, which is why there are many restrictions on their use. These restrictions create challenges in the market’s growth. Some of the adverse effects of using TPO-RAs are rebound thrombocytopenia, thrombocytosis, thrombosis & thromboembolic complications, increase in bone marrow reticulin, antibody formation, cataracts, and transaminase elevation.

Regional Insights

North America dominated the thrombopoietin receptor agonists market in 2023.

North America’s dominance reflects its actions in developing advanced healthcare systems, research and development for better therapeutics, actions taken to increase the reach of healthcare services, and the presence of market key players. Countries like the U.S. and Canada contribute significantly to the market’s growth. The U.S. dominated the thrombopoietin receptor agonists market in North America in 2023, followed by Canada. The countries are making efforts to improve therapeutics due to the growing concern of chronic liver disease and cancer cases.

According to the American Cancer Society, there will be around 20,800 new cases of acute myeloid leukemia (AML) in the United States in 2024. Adults will have the majority of instances. An estimated 11,220 individuals will pass away with AML. Once more, adults will account for the majority of these deaths. The Government of Canada anticipated that 3,100 leukemia fatalities and 6,700 new leukemia cases will occur in Canada (excluding Quebec) in 2022. 77% of individuals with acute myeloid leukemia in Canada (not including Quebec) are expected to pass away within five years after receiving their diagnosis.

Asia Pacific is expected to grow at the fastest rate during the forecast period.

The thrombopoietin receptor agonists market is growing due to growing research and development in cancer and other health issues that require TPO-RA drugs. Apart from this, the population in the region is also growing significantly, which increases the manpower or number of patients. This increases the interest of the organizations and the governments to take major steps towards the improvement of the healthcare and pharmaceutical industry.

Segmental Insights

By indication, the acute myeloid leukemia (AML) segment is anticipated to grow rapidly in the thrombopoietin receptor agonists market during the forecast period. Induction and consolidation chemotherapy are highly myelosuppressive for acute myeloid leukemia (AML), and CIT is a common burden. A TPO-RA can be used safely and effectively in this case to reduce the risk of bleeding and the need for platelet transfusion. The market is anticipated to grow as the number of leukemia patients increases because more TPO-RA drugs will be used to treat the cancer.

By indication, the immune thrombocytopenia (ITP) segment is estimated to grow at a significant rate during the predicted timeframe. Second-line therapies for ITP include rituximab, splenectomy, and TPO-RAs. Thrombopoietin-receptor agonists (TPO-RAs) are currently the most sophisticated therapy for immunological thrombocytopenia. The findings of this study provide credence to the use of TPO-RAs as second-line therapy for chronic and persistent ITP patients who do not respond to or relapse following previous first-line ITP treatments. TPO-RAs are safe and efficient medications for the treatment of primary ITP.

By dosage form, the injectables segment held the largest share of the thrombopoietin receptor agonists market in 2023. Injectables have several benefits, which is why they are used by professionals for treatment. The dose is given via injectables, which reduces the time of reaction, and can be given directly to the site of action.

By dosage form, the oral segment is anticipated to grow at the fastest rate during the forecast period. Oral TPO-RA medications are gaining popularity in the healthcare industry. Oral medications do not require the presence of professionals and can be taken by the patients directly. Oral medicine also reduces the cost of the medication.

By end-use, the hospitals segment held the major share of the thrombopoietin receptor agonists market in 2023, and the segment is expected to grow at the fastest rate during the forecast period. Patients with CLG, AML, ITP, and other health issues are admitted to hospitals for treatment and health monitoring. Due to this, TPO-RAs are used mainly in hospitals. Apart from this, hospitals have all the resources for providing multidisciplinary care, due to which patients prefer hospitals over other healthcare facilities.

Recent Developments

• In July 2024, the National Medical Products Administration ("NMPA") of China authorized avatrombopag maleate tablets from Gyre Pharmaceuticals, an indirectly controlled subsidiary of Gyre, to treat thrombocytopenia ("TP") associated with chronic liver disease ("CLD") in adult patients undergoing elective diagnostic procedures or therapy, according to Gyre Therapeutics.
• In March 2024, the exclusive distribution rights in Japan for Doptelet®, a thrombopoietin receptor agonist (generic name: avatrombopag maleate), which has an additional indication of idiopathic thrombocytopenic purpura (immune thrombocytopenia), are granted by an agreement between Asahi Kasei Pharma and Swedish Orphan Biovitrum Japan Co., Ltd. (Sobi Japan).

Top Companies in the Thrombopoietin Receptor Agonists Market

• Novartis
• Shionogi Co., Ltd.
• Jiangsu Hengrui Pharmaceuticals
• Shanghai Fosun Pharmaceutical
• CP Guojian Pharmaceutical Co., Ltd.
• Grand Pharmaceutical
• Sichuan Kelun Pharmaceutical
• Qilu Pharmaceutical
• Chia Tai Tianqing Pharmaceutical
• Chugai Pharmace
• Hetero
• Teva Pharmaceuticals
• Kyowa Kirin
• Amgen
• Actavis Laboratories
• Zhejiang Huahai Pharmaceutical Co., Ltd.
• Amneal Pharmaceuticals
• AkaRx
• 3SBio
• Shionogi
• Annora Pharma

Segments Covered in the Report

By Indication

• Acute Myeloid Leukemia (AML)
• Immune Thrombocytopenia (ITP)
• Myelodysplastic Syndromes (MDS)
• Aplastic Anemia

By Dosage Form

• Injectable
• Oral

By End-user

• Hospitals
• Clinics
• Pharmacies

By Region

• North America
  • U.S.
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait